- PLN1.31bn
- PLN1.22bn
- PLN216.57m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 18.06 | ||
| PEG Ratio (f) | 0.2 | ||
| EPS Growth (f) | 806.37% | ||
| Dividend Yield (f) | 0.34% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.54 | ||
| Price to Tang. Book | 2.59 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.67 | ||
| EV to EBITDA | 15.94 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 4.15% | ||
| Return on Equity | 3.79% | ||
| Operating Margin | 8.09% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | PLNm | 102.25 | 159.99 | 199.11 | 194.59 | 216.57 | 263.68 | 369.83 | 11.57% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -61.01 | n/a | n/a | n/a | n/a | n/a | +806.37 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Celon Pharma SA is a Poland-based company primarily engaged in the pharmaceuticals manufacture. The Company focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The Company's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The Company is a subsidiary of Glatton sp z o o.
Directors
- Robert Rzeminski CSU
- Maciej Wieczorek CMG
- Jacek Glinka VMG (56)
- Dorota Zwolinska FID
- Krzysztof Kaczmarczyk IND (45)
- Boguslaw Galewski SUB (59)
- Artur Wieczorek SUB
- Urszula Wieczorek SUB
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- October 25th, 2012
- Public Since
- December 1st, 2016
- No. of Employees
- 562
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Warsaw Stock Exchange- Shares in Issue
- 51,056,500
- Address
- ul. Ogrodowa 2A, Kielpin, 05-092
- Web
- https://celonpharma.com/
- Phone
- +48 227515933
- Contact
- Malgorzata Siewierska
- Auditors
- Ernst & Young Audyt Polska Sp z o.o.
Upcoming Events for CLN
Q1 2025 Celon Pharma SA Earnings Release
Half Year 2025 Celon Pharma SA Earnings Release
Similar to CLN
7Fit SA
Warsaw Stock Exchange
Bioceltix SA
Warsaw Stock Exchange
Biogened SA
Warsaw Stock Exchange
Cannabis Poland SA
Warsaw Stock Exchange
Cosma SA
Warsaw Stock Exchange
FAQ
What is the Celon Pharma SA share price?
As of Today at 19:50 UTC, shares in Celon Pharma SA are trading at PLN25.70. This share price information is delayed by 15 minutes.
How has the Celon Pharma SA share price performed this year?
Shares in Celon Pharma SA last closed at PLN25.70 and the price had moved by +70.45% over the past 365 days. In terms of relative price strength the Celon Pharma SA share price has outperformed the FTSE Global All Cap Index by +66.19% over the past year.
What are the analyst and broker recommendations for Celon Pharma SA?
The overall consensus recommendation for Celon Pharma SA is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Celon Pharma SA dividend yield?
The Celon Pharma SA dividend yield is 0.31% based on the trailing twelve month period.
Does Celon Pharma SA pay a dividend?
Last year, Celon Pharma SA paid a total dividend of PLN0.08, and it currently has a trailing dividend yield of 0.31%. We do not have any data on when Celon Pharma SA is to next pay dividends.
When does Celon Pharma SA next pay dividends?
We do not have data on when Celon Pharma SA is to next pay dividends. The historic dividend yield on Celon Pharma SA shares is currently 0.31%.
How do I buy Celon Pharma SA shares?
To buy shares in Celon Pharma SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Celon Pharma SA?
As of the previous close price of PLN25.70, shares in Celon Pharma SA had a market capitalisation of PLN1.31bn.
Where are Celon Pharma SA shares listed?
Here are the trading details for Celon Pharma SA:
- Country of listing: Poland
- Exchange: WSE
- Ticker Symbol: CLN
What kind of share is Celon Pharma SA?
Based on an overall assessment of its quality, value and momentum Celon Pharma SA is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Celon Pharma SA share price forecast for 2025?
The analyst consensus target price for shares in Celon Pharma SA is PLN27.20. That is 5.84% above the last closing price of PLN25.70.
Analysts covering Celon Pharma SA currently have a consensus Earnings Per Share (EPS) forecast of PLN0.16 for the next financial year.
Find out moreWhat is the trend in the Celon Pharma SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Celon Pharma SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -12.93%.
As of the last closing price of PLN25.70, shares in Celon Pharma SA were trading -3.12% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Celon Pharma SA PE Ratio?
The Celon Pharma SA PE ratio based on its reported earnings over the past 12 months is 18.06. The shares last closed at PLN25.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Celon Pharma SA?
Celon Pharma SA's management team is headed by:
- Robert Rzeminski - CSU
- Maciej Wieczorek - CMG
- Jacek Glinka - VMG
- Dorota Zwolinska - FID
- Krzysztof Kaczmarczyk - IND
- Boguslaw Galewski - SUB
- Artur Wieczorek - SUB
- Urszula Wieczorek - SUB